mRNA/saRNA Manufacturing - RNA Therapeutic Delivery & Applications

Aldevron Chief Scientific Officer, Venkata Indurthi, Ph.D., shared his knowledge and experience with manufacturing RNA in a webinar entitled, “mRNA/saRNA Manufacturing – Considerations to Accelerate the Path to Clinic.” As a follow up, Dr. Indurthi sat down with Communications Sr. Director, Ellen Shafer, for an interview to answer dozens of questions he received during the presentation.

Dr. Indurthi shares insight into RNA delivery and the breadth of applications–present and future–that innovations in the field are enabling. While RNA was always relevant and valued as a modality, the COVID-19 pandemic served as a catalyst and accelerated the field by 10-to-15 years. Whether you are developing a vaccine or therapeutic, optimizing elements such as the capping process–whether enzymatic or manufactured–is crucial for increasing the protein expression.

While self-amplifying RNA (saRNA) still in its infancy, its ability to lower dose sizes, and increase patient accessibility in doing so, holds great potential for reaching larger patient populations and enabling treatments in less affluent regions. Learn more about messenger RNA (mRNA) and self-amplifying RNA (saRNA) development and manufacturing processes and how different projects' needs may vary.